Psychedelic Science Newsletter
Issue #28March 16, 20267 studies

Psilocybin beats nicotine patches 40.5% vs 10% for quitting smoking

Psychedelic research hit several major milestones this week, with studies spanning everything from smoking cessation to postpartum depression to the evolutionary origins of magic mushrooms.

πŸ„ Psilocybin outperforms nicotine patches for smoking cessation

  • 40.5% of smokers given one dose of psilocybin (30mg) plus therapy stayed smoke-free for 6 months, compared to just 10% using nicotine patches plus the same therapy

  • The single psilocybin session was 6 times more effective than standard nicotine replacement (odds ratio 6.12) in this 82-person trial

  • No serious side effects were reported from either treatment, suggesting psilocybin's safety profile in this context

Why it matters: These abstinence rates are higher than most conventional smoking cessation treatments, potentially offering a breakthrough for the 480,000 Americans who die from tobacco use annually.

πŸ₯ˆ Top 2% journal πŸ”— JAMA network open πŸ—“οΈ Mar 10

Key Findings

🧠 Female rats show heightened sensitivity to psychedelic 5-MeO-DMT

  • Female rats demonstrated markedly enhanced sensitivity to low-dose 5-MeO-DMT (0.1 mg/kg), showing extensive brain activity changes that were largely absent in males at the same dose

  • Brain imaging revealed peak effects occurred within the first 10 minutes after injection, aligning with the compound's rapid-acting therapeutic potential

  • This represents the first fMRI study of 5-MeO-DMT in any species, revealing previously unknown sex differences in psychedelic response

πŸ’‘ Sex differences in psychedelic sensitivity could inform personalized dosing strategies for therapeutic applications.
πŸŽ–οΈ Top 10% journal πŸ”— Neuropharmacology πŸ—“οΈ Mar 9

πŸ•ŠοΈ Psychedelics linked to reduced fear of death

  • Meta-analysis of 8 studies found psychedelics associated with moderate-to-large reductions in death anxiety (Cohen's d = 0.70)

  • Mystical experiences during psychedelic sessions were particularly associated with decreased death anxiety

  • Effects were stronger in clinical settings compared to general population use

πŸ’‘ These findings support psychedelic therapy's potential for end-of-life care and existential distress.
πŸŽ–οΈ Top 10% journal πŸ”— Journal of psychopharmacology (Oxford, England) πŸ—“οΈ Mar 9

🌿 Scientists discover magic mushroom's closest wild relative in Africa

  • Researchers identified Psilocybe ochraceocentrata as the closest wild relative to cultivated Psilocybe cubensis, last sharing a common ancestor approximately 1.5 million years ago

  • Both species are associated with large herbivore dung, suggesting their common ancestor was already adapted to this ecological niche

  • DNA analysis challenges previous assumptions about the geographic origins and evolutionary history of psychedelic mushrooms

πŸ’‘ This discovery provides new genetic resources for psychedelic mushroom research and clarifies their evolutionary origins.
πŸŽ–οΈ Top 10% journal πŸ”— Proceedings. Biological sciences πŸ—“οΈ Mar 12

πŸ‘Ά Ketamine shows promise for PTSD patients in real-world settings

  • 202 real-world patients with PTSD reported improvements across multiple trauma symptoms after ketamine treatment

  • Patients with PTSD had more severe depression, anxiety, and sleep problems before treatment but responded just as well as those without PTSD

  • Most PTSD patients received additional psychotherapy, though improvements were also reported by those receiving ketamine alone

πŸ’‘ Real-world evidence suggests ketamine may help reprocess trauma, though controlled studies are needed to confirm these patient-reported benefits.
Top 30% journal πŸ”— Eur J Trauma Dissociation πŸ—“οΈ Mar 9

πŸ§ͺ Ayahuasca linked to improved memory and cognitive flexibility

  • Systematic review of 16 studies found short-term improvements in working memory and cognitive flexibility following ayahuasca use

  • Long-term studies generally found no cognitive deficits, with some reporting enhanced memory and executive function

  • Social cognition studies showed increased empathy and emotion recognition, though experimental studies only observed faster reaction times

πŸ’‘ Ayahuasca appears to enhance rather than impair cognitive function, though methodological limitations require more rigorous controlled studies.
πŸŽ–οΈ Top 10% journal πŸ”— Journal of psychopharmacology (Oxford, England) πŸ—“οΈ Mar 9

⚠️ Hallucinogen use linked to complex clinical outcomes in adolescent psychosis

  • 14.3% of adolescents with early-onset psychosis had used hallucinogens, with rates varying widely across studies

  • Hallucinogen use was consistently associated with polysubstance use, suicidality, conduct disorder, and reduced educational attainment

  • In general population studies, associations between hallucinogen use and psychotic symptoms were weak and largely disappeared after accounting for other drugs and genetic vulnerability

πŸ’‘ Hallucinogens may contribute to symptom complexity in genetically predisposed youth rather than serving as isolated causal triggers.
πŸŽ–οΈ Top 10% journal πŸ”— Child and adolescent psychiatry and mental health πŸ—“οΈ Mar 9

Implications

This week's research reveals psychedelics' therapeutic potential across multiple conditions while highlighting important safety considerations, particularly for vulnerable populations. The striking success of psilocybin for smoking cessation, combined with emerging evidence for PTSD and cognitive benefits, suggests these compounds may offer novel treatment pathwaysβ€”though sex differences, dosing protocols, and long-term effects require careful study as the field advances toward clinical applications.

Studies in this issue

Primary sources used for this newsletter.

  1. Psilocybin or Nicotine Patch for Quitting Smoking: A Small Randomized Trial
    main storyJAMA network open2026-03-10PMID 41805956
  2. Finding the closest wild relative of the cultivated 'magic mushroom' Psilocybe cubensis in Africa
    key findingProceedings. Biological sciences2026-03-12PMID 41818815
  3. Self-Reported Improvements in PTSD, Depression, Anxiety, and Sleep in Patients Using Medical Ketamine and the Impact of Additional Therapies
    key findingEuropean journal of trauma & dissociation = Revue europeenne du trauma et de la dissociation2026-03-09PMID 41800353
  4. Unusual experiences and early psychosis linked to hallucinogen use in teenagers
    key findingChild and adolescent psychiatry and mental health2026-03-09PMID 41796365
  5. Psychedelic experiences and their link to fear of death: A combined analysis of studies
    key findingJournal of psychopharmacology (Oxford, England)2026-03-09PMID 41797724
  6. Ayahuasca's effects on thinking skills and understanding others: A systematic review
    key findingJournal of psychopharmacology (Oxford, England)2026-03-09PMID 41800655